Fig. 6: Emapalumab displays therapeutic effect in humanized mice developing CRS.
a Schematic representation of the experimental design: hGM-CSF/hIL3 NOG mice were infused with irradiated FF-Luciferase positive sub-acutely irradiated Daudi cells (10 × 106 cells/mouse. n = 10 total humanized mice) at Day-2 and treated with 10 × 106 CAR.CD19-T cells/mouse in the presence of either 100 mg/kg/day emapalumab (n = 4) or vehicle (n = 4). Two mice were considered as for negative control infused only with DAUDI cells. b IFNγ, c IL-6, d CXCL9/MIG and e CXCL10/IP-10 levels were measured on peripheral blood of negative control (n = 2), treated with 10×106 CAR.CD19-T cells/mouse in the presence of either 100 mg/kg/day emapalumab (n = 4) or vehicle (n = 4) mice at Day+3 and Day+4 after effector T-cell infusion. Student’s t-test was employed to calculate statistically significant differences between groups. Data are expressed as mean ± SD. All data above described were compared by a two-tailed Student t-test and p value <0.05 was considered statistically significant. f Kaplan–Meier survival curve analysis of CAR.CD19-T cell-treated mice without emapalumab (black line) or with emapalumab (red line). Source data are provided as a Source Data file.
